A trial to evaluate the safety and effectiveness of AeriSeal® System to block collateral ventilation (CV) and convert a severe emphysema patient from CV+ to CV- status.
CONVERT II is currently enrolling patients in sites around the world.
This study has 24 locations:
United Kingdom
United States
Orlando, Florida, United States, 32806
Orlando Health
Mark Vollenweider, MD
Boston, Massachusetts, United States, 02115
Beth Israel Deaconess Medical Center
Adnan Majid, MD
Boston, Massachusetts, United States, 02115
Brigham Lung Center
Majid Shafiq, MD
Cleveland, Ohio, United States, 44106
Cleveland VA Northeast
Christopher Di Felice, MD
Philadelphia, Pennsylvania, United States, 19107
Penn Medicine
Kevin Ma, MD
Philadelphia, Pennsylvania, United States, 19140
Temple University
Gerard Criner, MD
Falls Church, Virginia, United States, 22042
Inova Fairfax Hospital
Priya Patel, MD
Australia
Austria
Denmark
France
Germany
Essen, Germany, 45239
Ruhrlandklinik - West German Lung Center
Ruediger Karpf-Wissel, MD
Heidelberg, Germany, 69126
Thoraxklinik am Universitats klinikum Heidelberg
Felix Herth, MD, PhD
Italy
Brescia, Italy, 25123
ASST Spedali Civili, University Hospital
Michela Bezzi, MD, PhD
Netherlands
Groningen, Netherlands
University Medical Center Groningen
Dirk-Jan Slebos, MD, PhD
Spain
Valencia, Spain, 46026
Hospital Universitario y Politecnico La Fe
Enrique Cases Viedma, MD, PhD
Please visit clinicaltrials.gov/study/NCT06035120 for additional trial information.
CONVERT II Clinical Trial Information
Review the clinical trial brochure to see the study design and patient eligibility criteria.